Heldens J G, Kersten A J, Weststrate M W, van den Hoven R
Fort Dodge Animal Holland, Weesp, The Netherlands.
Vet Q. 2001 Nov;23(4):210-7. doi: 10.1080/01652176.2001.9695116.
An adjuvanted vaccine containing inactivated equine influenza, herpesvirus antigens, and tetanus toxoid was administered to young seronegative foals of 8 months of age by deep intramuscular injection in the neck (Group A). The first two vaccinations were given 4 weeks apart. The third was administered 6 months later. Another group of foals (Group B) was vaccinated according to the same scheme at the same time with monovalent equine herpes virus (EHV) vaccine (EHV1.4) vaccine. Antibody responses to the equine influenza (single radial haemolysis; SRH) and tetanus (ToBi ELISA) components of the vaccines were examined from first vaccination until 1 year after the third vaccination. The influenza components of the combination vaccine induced high antibody titres at two weeks after the second vaccination whereafter titres declined until the time of the third vaccination. After the third vaccination, the titres rose rapidly again to remain high for at least 1 year. Antibody titres against tetanus peaked only after the third vaccination but remained high enough to offer protective immunity for at least 1 year. Foals vaccinated with monovalent EHV1.4 remained seronegative for influenza and tetanus throughout the study. Four and a half months after the third vaccination of groups A and B, a third group of animals was vaccinated twice with monovalent EHV1.4 vaccine 4 weeks apart (Group C). Two weeks after the administration of the second dose in the later group, all groups (A, B, C and an unvaccinated control group D) were challenged with EHV-4. Vaccinated foals (Group A, B, C) showed a clear reduction of clinical symptoms and virus excretion after EHV-4 challenge compared with the unvaccinated control foals. No difference could be demonstrated among the vaccinated groups, suggesting that the combination vaccine protects as well as the monovalent vaccine. In EHV1.4-vaccinated foals both antigenic fractions induced clear protection up to 6 months after vaccination (9). It can therefore be anticipated that the efficacy of the combination vaccine against EHV-1 challenge is similar to the efficacy against EHV-1 induced by EHV1.4 vaccination.
通过颈部深部肌肉注射，给8月龄血清阴性的幼驹（A组）接种一种含有灭活马流感、疱疹病毒抗原和破伤风类毒素的佐剂疫苗。前两次接种间隔4周。第三次接种在6个月后进行。另一组幼驹（B组）在同一时间按照相同方案接种单价马疱疹病毒（EHV）疫苗（EHV1.4）。从首次接种到第三次接种后1年，检测疫苗中马流感（单向辐射溶血法；SRH）和破伤风（ToBi ELISA）成分的抗体反应。联合疫苗中的流感成分在第二次接种后两周诱导出高抗体滴度，此后滴度下降，直至第三次接种时。第三次接种后，滴度再次迅速上升，并至少维持1年的高水平。破伤风抗体滴度仅在第三次接种后达到峰值，但仍保持足够高的水平，以提供至少1年的保护性免疫。在整个研究过程中，接种单价EHV1.4的幼驹对流感和破伤风仍呈血清阴性。在A组和B组第三次接种后4个半月，第三组动物间隔4周接种两次单价EHV1.4疫苗（C组）。在C组接种第二剂疫苗两周后，所有组（A、B、C组和未接种的对照组D）用EHV - 4进行攻毒。与未接种的对照幼驹相比，接种疫苗的幼驹（A、B、C组）在EHV - 4攻毒后临床症状和病毒排泄明显减少。在接种疫苗的组之间未显示出差异，这表明联合疫苗与单价疫苗的保护效果相同。在接种EHV1.4的幼驹中，两种抗原成分在接种后6个月内均诱导出明显的保护作用（9）。因此，可以预期联合疫苗对EHV - 1攻毒的效果与EHV1.4接种诱导的对EHV - 1的效果相似。
